Roche and Nurix Collaborate on BTK Degrader Bexobrutideg for B-cell Malignancies
Roche has entered a collaboration with Nurix Therapeutics to co-develop bexobrutideg, BTK degrader targeting B-cell malignancies, immunology, and neurology.
Therapeutic Area
Therapeutic area intelligence for B-cell Malignancies with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.